

Appendix: Patient Group Conflict of Interest Declaration

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

No outside assistance was utilized to complete this submission. This submission was completed by CLF staff and volunteers. The only outside input for this submission came from the patients, caregivers and health care professionals who responded to the CLF's online survey.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

No outside assistance was utilized to collect or analyze data used in this submission. This submission was completed by CLF staff and volunteers. The only outside input for this submission came from the patients, caregivers and health care professionals who responded to the CLF's online survey.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

The Canadian Liver Foundation (CLF) is committed to bringing liver research to life for all Canadians through liver research, education, patient support and advocacy. The CLF receives funding from a variety of sources with the majority coming from donations from individuals across the country. We use these funds to support CLF liver awareness, education, patient support and research grant programs.

The CLF receives some program funding in the form of unrestricted educational grants from pharmaceutical companies. Grant agreements are established in support of activities initiated by the CLF and prohibit the funder from having any input or influence in program objectives or deliverables.

Company
Eisai Limited
Bayer Inc.
Sirtex Medical Europe
BTG International Canada
Bristol-Myers Squibb Canada
Ipsen Biopharmaceuticals Canada

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Karen Seto
Position: Director, Partnerships & Development
Patient Group: Canadian Liver Foundation
Date: February 20, 2019

Patient Input Template for CADTH CDR and pCODR

Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

Note that this same information can be used for our submissions for:

Abiraterone (Zytiga) for prostate cancer

Lenvatinib (Lenvima) for Hepatocellular Carcinoma

Larotrectinib

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

We contracted an independent contractor to interview patients who were taking Lenvatinib for hepatocellular carcinoma for a qualitative submission.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

The consultant collected and analyzed the interviews with patients in order to prepare the quantitative submission for hepatocellular carcinoma.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company
Eisai
Bayer
Janssen

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Jackie Manthorne
Position: President & CEO
Patient Group: Canadian Cancer Survivor Network
Date: March 29, 2019